Michael A. Metzger

Michael A. Metzger

DirectoratSyndax Pharmaceuticals· In proxies 2021–2025

Pay in FY2025-8% from the year before · Syndax Pharmaceuticals stock +58.9% the same year

Michael A. Metzger was paid $7.1M in FY2025 (Dec), down 8%. Syndax Pharmaceuticals stock rose 58.9% that year.

Pay$100 in the stock at the end of FY20 → $94
Pay is from the Summary Compensation Table of each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Pyxis OncologyPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Syndax PharmaceuticalsPublic company · 5 yr
    • Chief Executive Officer2021 – Present · 5 yrStock in role -41%
  3. Pyxis OncologyPublic company
    • Director? – PresentNo stock prices for these years
  4. CTI Biopharma Corp.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Pyxis OncologyDirector · 1 yr on the boardIndependentAudit, Compensation—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?